Department of Pharmaceutics, Rajiv Academy for Pharmacy, Mathura, India.
Expert Opin Drug Deliv. 2012 Jul;9(7):863-78. doi: 10.1517/17425247.2012.693072. Epub 2012 Jun 5.
Microparticulate drug delivery systems have, due to their advantages, guided researchers across the globe to explore them as drug carriers. This has, sequentially, led to the development of microsponges in 1988. These porous microspheres were exclusively designed for chronotherapeutic topical drug delivery but attempts to utilize them for oral, pulmonary and parenteral drug delivery were also made. Researchers have extensively studied their properties and characteristics affecting the drug release and loading. Various advances were made with this carrier particle resulting in the development of various novel development techniques and carrier particles.
This review deals with the considerations of the drug material to be entrapped in microsponges, pharmaceutical considerations for fabrication of microsponges, their potential for oral drug delivery, clinical perspectives and also provides an insight on the recent advances made in this field and future prospect.
Clinical studies show that these carriers can increase drug efficacy. Due to their potential advantages over other carrier particles, microsponges form a prospective platform for the oral delivery of pharmaceuticals and biopharmaceuticals. Although these carriers have several advantages, they too possess some drawbacks which limit their commercialization for oral application.
由于微粒药物递送系统具有优势，全球的研究人员都在探索它们作为药物载体。这相继导致了 1988 年微海绵的发展。这些多孔微球专门设计用于定时局部药物递送，但也尝试将其用于口服、肺部和肠胃外药物递送。研究人员广泛研究了影响药物释放和负载的性质和特征。这种载体颗粒取得了各种进展，导致了各种新型开发技术和载体颗粒的发展。
这篇综述涉及到要包封在微海绵中的药物材料的考虑因素、用于制造微海绵的药物考虑因素、它们在口服药物递送方面的潜力、临床观点，并提供了对该领域的最新进展和未来前景的洞察。
临床研究表明，这些载体可以提高药物疗效。由于它们相对于其他载体颗粒具有潜在优势，微海绵为口服递药提供了一个有前景的平台，适用于药物和生物制药。尽管这些载体具有许多优点，但它们也存在一些限制其在口服应用中商业化的缺点。
